Peringkat dalam Saham
#40642
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies... Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.
Harga Saham
$0.00323826
Terakhir disinkronkan: 2026-08-12
Kapitalisasi Pasar
$104.81K
Perubahan (1 tahun)
-70.42%
Perdagangan Purple Biotech Ltd. (PPBT)
Laba untuk Purple Biotech Ltd. (PPBT)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari Purple Biotech Ltd., laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Purple Biotech Ltd. dari 2026 hingga 2026
Laba pada akhir setiap tahun
| Tahun |
Laba |
Mengubah |
|
Tidak cukup data untuk tanggal yang disediakan. |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan |
Laba |
Perbedaan Laba |
Negara |
|
|
$5.27B |
-
|
US
|
|
|
$1.95B |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
- |
-
|
KR
|
|
|
$3.01B |
-
|
BE
|
